2) Diagnostic PET/SPECT【Oncology PET】
NKO-035 PET clinical research
New PET probe (F-18 NKO-035 injection), which has high selectivity for amino acid transporter (LAT1) highly expressed in cancer cells, has developed in collaboration with department of Bio-systems Pharmacology (Prof. Yoshikatsu Kanai), and stable mass production was enabled by new labelling method.
In November 2019, the world's first in human clinical trial was conducted using F-18 NKO-035 solution in healthy adults to confirm its safety in humans.
In the future, by conducting clinical trials to confirm the efficacy in cancer patients, we can reduce false-positive findings for inflammatory lesions, which were difficult to accurately being diagnosed with conventional FDG-PET. It is expected to lead to highly accurate cancer diagnosis.
|Radiolabeled amino acid analog||Radiolabeled glucose analog|
|Tracer uptake in tumor tissues||High||High|
|Tracer uptake in inflamed lesions||None||Moderate ~ high|
Comparison between new PET probe and conventional PET probe